REFERENCIAS BIBLIOGRÁFICAS DE AV SLINDA – MÉXICO
1. Lidegaard Ø, Milsom I, Geirsson R, Skjeldestad F. Hormonal contraception and venous thromboembolism. Acta Obstet Gynecol Scand. 2012; 91(7): 769-79. 2. Observatorio Mundial de Obesidad, disponible en h-ttp-s:/-/data-.worldobesity-.org-. Actualizado en Sept/2021. 3. ENSANUT. Encuesta Nacional de Salud y Nutrición 2018. Presentación de resultados. INEGI. Instituto Nacional de Salud. Secretaría de Salud. 4. Pomp E, le Cessie S, Rosendaal F, Doggen C. Risk of venous thrombosis: obesity and its joint effect with oral contracptive use and prothrombotic mutations. Br J Haematol. 2007; 139(2): 289-96. 5. International Diabetes Federal. Atlas de la Diabetes de la FID. 9a. Edición. 2019. 6. Wyss F, López P, Coca A. Consenso para el control del riesgo cardiovascular en Centroamérica y el Caribe. SCCH. 2016 7. NDA 211367 Multi-disciplinary review and evaluation NDA 211367 Slynd (drospirenone). 8. Duijkers I, Heger-Mahn D, Drouin D, et al. Maintenance of ovulation inhibition with a new progestogen only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception. 2016; 93(4): 303-309. 9. Palacios S, Regidor P, Colli E, et al. Oestrogen-free oral contraception with a 4 mg drospirenone-only pill: new data and a review of the literature. Eur J Contracept Reprod Health Care. 2020; 25(3): 221-227. 10. Archer D, Ahrendt H, Drouin D. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015; 92(5): 439-444. 11. Palacios S, Colli E, Regidor P. Multicenter, phase III trial son the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand. 2019; 98: 1549-1557. 12. Kimble T, Burke A, Barnhart K, et al. A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestine-only pill drospirenone 4 mg using a 24/4-day régimen. Contracept X. 2020; 2: 10020. 13. Apter D, Colli E, Gemzell-Danielsson K, Peters K. Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase. Contraception. 2020; 101(6): 412-419. 14. Laboratorios Leon Farma. CF111/301. Clinical Study Report. 2014. 15. Laboratorios Leon Farma, S.A. A pivotal, multicenter, doublé-blind, doublé dummy, randomised trial on the contraceptive efficacy, tolerability and safety of LF111 (Drospirenone) over 9 cycles in comparison with desogestrel 0.075 mg. Study 302. 2014. 16. Laboratorios Leon Farma, S.A. A pivotal, multicenter, non-comprative trial on the contraceptive efficacy, safety, tolerability and pharmacokinetis of LF111 (Drospirenone 4.0 mg) during 13 cycles (Study CF111/303). Clinical Trial Report. 2018. 17. FDA Approval letter Slynd. Application number 211367Orig1s000. Center for drug evaluation and research. July 27, 2018. 18. Caiyan W, Wen D, Qinping L, et al. [Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24+4 day régimen in China]. Zhonghua Fu Chan Ke Za Zhi. 2014; 49(5): 355-9. Chinese. 19. Korver T, Klipping C, Heger-Mahn D, et al. Maintenance of ovulation inhibition with the 75mcg desogestrel-only pill (Cerazette) after scheduled 12-h delays in Tablet intake. Contraception. 2005; 71(1): 8-13. 20. Rice C, Killick S, Dieben T, et al. A comparison of the inhibition of ovulation achieved by desogestrel 75 mcg and levonorgestrel 30 mcg daily. Human Reprod. 1999; 14(4): 982-5. 21. Milsom I, Korver T. Ovulation incidence with oral contraceptives a literatura review. J Fam Plann Reprod Health Care. 2008; 34(4): 237-46. 22. Krattenmacher R. Drospirenone: pharmacology and pharmaccokinetics of a unique progestogen. Contraception. 2000; 62(1):29-38.